ArticleInternational journal of surgery case reports2026
Recurrent pancreatic acinar cell carcinoma following a 7-year disease-free interval: A case report and literature review.
Article in International journal of surgery case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and importance: Pancreatic acinar cell carcinoma (PACC) is a rare malignant pancreatic tumor, accounting for only 1% of all pancreatic neoplasms. It has distinctive clinical, radiological, and histological features. Case presentation: Here, we report a case of PACC diagnosed 7 years after surgical treatment for pancreatic ductal adenocarcinoma (PDAC). The recurrence was suspected during routine follow-up via abdominal computed tomography scan, which showed a local mass without biliary ducts dilation, vascular involvement, or any specific radiological signs. However, clinical examination and laboratory workup, including tumor markers (CA 19-9 and carcinoembryonic antigen), were normal. By comparing samples obtained via endoscopic ultrasound fine-needle aspiration of the pancreatic mass to the histopathological findings of the prior duodenopancreatectomy, a diagnosis of local recurrence of previously misdiagnosed PACC was established. Clinical discussion: PACC is a rare pancreatic epithelial malignancy (1%), for which radical surgical resection remains the treatment of choice. However, it is usually diagnosed at an advanced stage (with metastasis). The most common differential diagnoses include pancreatic adenocarcinoma, pancreatic neuroendocrine tumors, solid pseudopapillary neoplasms, and pancreatoblastoma in the pediatric population. Histopathological examination combined with immunohistochemical staining remains the cornerstone for establishing the diagnosis. In our case, ultrasound-guided fine needle aspiration of the pancreatic mass, compared to the previous duodenopancreatectomy, led to the diagnosis of a local recurrence of a previously misdiagnosed initially as PDAC, with the longest survival (84 months) ever described in the literature. Conclusions: Due to its rarity, PACC remains a diagnostic challenge. It has a better prognosis than PDAC; radical resection is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.